Regorafenib from Bayer Granted Priority Review in the U.S. for Second-Line Treatment of Liver Cancer

Bayer Develops Companion Diagnostic Test for Cancer Patients Together with Leica Biosystems

Companion diagnostics network supports Bayer’s personalized medicine approach

Monsanto Shareowners Approve Merger with Bayer

Key Milestone in Merger to Create a Global Leader in Agriculture / Close of Transaction Expected by the End of 2017

Robert LaCaze to be Executive Vice President of New Oncology Strategic Business Unit at Pharmaceuticals Division of Bayer

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions

Big Data meets Life Sciences

Key topics in medical and plant research: disease genomics, herbicide resistance, big data analysis for new therapies / Experiencing and understanding the fascination of science: all topics also available in the online edition of research with animated graphics, videos and photo galleries

Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter Into Agreement for Purchase of U.S. Cydectin® Product Portfolio

Ten Abstracts on the Use of Bayer’s Xarelto® in Different Patient Populations Accepted for Presentation at ASH 2016